Sangamo Therapeutics Files 8-K

Ticker: SGMO · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1001233

Sangamo Therapeutics, Inc 8-K Filing Summary
FieldDetail
CompanySangamo Therapeutics, Inc (SGMO)
Form Type8-K
Filed DateOct 4, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulation-fd

Related Tickers: SGMO

TL;DR

SGMO filed an 8-K for Reg FD disclosure, no major news yet.

AI Summary

On October 4, 2024, Sangamo Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information that may be of interest to investors. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Sangamo Therapeutics has disclosed information under Regulation FD, which could contain important updates for investors regarding company communications.

Risk Assessment

Risk Level: low — The filing is a standard disclosure under Regulation FD and does not, in itself, indicate any new risks or material adverse events.

Key Players & Entities

  • SANGAMO THERAPEUTICS, INC. (company) — Registrant
  • October 4, 2024 (date) — Date of earliest event reported
  • 501 Canal Blvd. (location) — Principal executive offices address
  • Richmond, California (location) — Principal executive offices city and state
  • 000-30171 (other) — Commission File Number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide a Regulation FD Disclosure, indicating the company is making material information available to the public.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is October 4, 2024.

What is Sangamo Therapeutics, Inc.'s principal executive office address?

The principal executive office address is 501 Canal Blvd., Richmond, California 94804.

What is the Commission File Number for Sangamo Therapeutics, Inc.?

The Commission File Number for Sangamo Therapeutics, Inc. is 000-30171.

Does this filing detail any specific financial transactions or material events?

Based on the provided excerpt, this filing is a Regulation FD Disclosure and does not detail specific financial transactions or material events.

Filing Stats: 1,124 words · 4 min read · ~4 pages · Grade level 12.2 · Accepted 2024-10-04 16:03:54

Key Financial Figures

  • $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Global

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 4, 2024, the Company filed a Certificate of Amendment of the Restated Certificate of Incorporation with the Delaware Secretary of State, which increased the number of authorized shares of the Common Stock from 640,000,000 to 960,000,000 shares (the "Common Stock Increase Amendment"). At the Company's 2024 annual meeting of stockholders held on June 4, 2024 (the "2024 Annual Meeting"), the holders of a majority of the outstanding shares of Common Stock of the Company approved the Common Stock Increase Amendment. In connection with the 2024 Annual Meeting, Sangamo filed a proxy statement on Schedule 14A (the "Proxy Statement") on April 19, 2024. The Proxy Statement described the voting threshold needed to approve the Common Stock Increase Amendment as requiring an affirmative vote of a majority of all votes cast at the 2024 Annual Meeting. The Company believes that the Proxy Statement accurately described the vote required to adopt the Common Stock Increase Amendment under a recently enacted provision of the Delaware General Corporation Law (the "DGCL") (Section 242(d)(2)), which became effective on August 1, 2023. On June 3, 2024, the law firms of Pomerantz LLP and Fields Kupka & Shukurov LLP filed a stockholder class action complaint against the Company and the Company's board of directors in the Delaware Court of Chancery ("Court of Chancery") on behalf of one purported stockholder of the Company. Among other matters, the complaint alleged that because the Proxy Statement had specified that a majority-of-votes-cast voting standard was required for the approval of the Common Stock Increase Amendment, rather than a majority-of-outstanding-shares voting standard, the Common Stock Increase Amendment and any issuances of Common Stock pursuant thereto were and are not validly authorized, despite the fact that both a majority of the votes cast at the 2024 Annual Meeting and a majority of the outstanding shares of Common Stock

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Section 205 Verified Petition 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: October 4, 2024 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Senior Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.